VIFOR-PHARMA-GROUP
27.9.2021 08:04:09 CEST | Business Wire | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing authorization approval for TAVNEOS® for the treatment of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main types of ANCA-associated vasculitis, a rare and severe autoimmune renal disease with high unmet medical need.
“We are delighted that TAVNEOS® has been approved in Japan, the first market worldwide, and congratulate our partner Kissei for this significant milestone,” said Abbas Hussain, CEO of Vifor Pharma Group. “ANCA-associated vasculitis is officially designated an intractable disease in Japan, indicating a rare disease without any effective treatment but for which long-term treatment is required. There is significant unmet medical need of over 10,000 patients in Japan, and we believe in the potential of TAVNEOS® for treating it. We are confident that Kissei will fully focus on bringing this breakthrough treatment to this patient population, helping them lead better, healthier lives.”
The approval is based on the marketing authorization application filing by Kissei which was supported by positive clinical data from the pivotal phase-III trial ADVOCATE in a total of 331 patients with MPA and GPA in 18 countries and regions, including Japan. TAVNEOS® demonstrated superiority over standard of care at week 52 based on Birmingham Vasculitis Activity Score (BVAS).
VFMCRP holds the rights to commercialize TAVNEOS® outside the U.S.. In June 2017, VFMCRP granted Kissei the exclusive right to develop and commercialize TAVNEOS® in Japan. Kissei expects to begin to market TAVNEOS® as soon as possible following NHI price listing. Outside Japan, TAVNEOS is currently in regulatory review with various agencies, including the U.S. Food and Drug Administration and the European Medicines Agency.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company with approximately 70 years of history. Based on its management philosophy, “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees”, Kissei is concentrating on providing innovative pharmaceuticals to patients worldwide as a strongly R&D-oriented corporation. Kissei is engaged in R&D and licensing activities in the field of nephrology/dialysis, urology, and unmet medical needs in other disease areas. Kissei has an established collaboration with VFMCRP for sucroferric oxyhydroxide which Kissei fully developed in Japan as P-TOL® (known as Velphoro® in Europe/US) for the treatment of hyperphosphatemia. Since the launch in 2015, the market share of P-TOL® has been steadily expanding in Japan. For more information about Kissei Pharmaceutical, please visit www.kissei.co.jp .
About ChemoCentryx Inc.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Besides ChemoCentryx’s lead drug candidate, avacopan, ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
About ANCA-associated vasculitis
ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. Currently, treatment for ANCA-associated vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids (steroids) for prolonged periods of time, which can be associated with significant clinical risk including death from infection.
About TAVNEOS® (avacopan)
Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment, C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of inflammation. Moreover, avacopan’s selective inhibition of only the C5aR1 leaves the beneficial C5a l pathway through the C5L2 receptor functioning normally.
ChemoCentryx is also developing avacopan for the treatment of patients with C3 Glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan-drug designation for ANCA-associated vasculitis, C3G and atypical hemolytic uremic syndrome. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. In October 2020, European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for avacopan for the treatment of patients with ANCA-associated vasculitis (granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210926005078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The smarter E Europe: The Special Exhibit Renewables 24/7 Shows How a Renewable Energy Supply Is Possible21.4.2026 13:00:00 CEST | Press release
The current geopolitical situation once again highlights the risks of depending on fossil fuels and the increasing need to transform our energy supply. Solar and wind power have long been established as cost-efficient energy sources, and the International Energy Agency (IEA) has predicted a global 2.6-fold capacity growth between 2022 and 2030. Against this backdrop, The smarter E Europe alliance of exhibitions will spotlight the feasibility of a renewable energy system from June 23–25 in Munich. The Special Exhibit Renewables 24/7 uses best practices, presentations and live demos to show how a round-the-clock renewable energy supply can be achieved. To kick off the exhibition on June 23, The smarter E Europe will present an exclusive accompanying study, conducted in collaboration with the Fraunhofer Institute for Solar Energy Systems, that dispels common myths about system stability and provides scientific proof that such an energy system is viable. The study, Pathways to a Renewable
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Aventon Expands B2B Payment Terms Program to Germany with TreviPay21.4.2026 11:00:00 CEST | Press release
Expansion builds on North American program success and brings flexible invoicing and net terms to Aventon’s growing retailer network in Europe TreviPay, a global B2B payments infrastructure partner, today announced the expansion of its partnership with Aventon to support the launch of the Aventon Payment Terms program in Germany. Building on the success of Aventon’s existing program in the US and Canada, the new offering will give qualified B2B buyers in Germany access to invoicing and flexible payment terms designed to make purchasing easier and more predictable. As Aventon enters the German market and expands its presence in Europe, TreviPay will serve as the exclusive provider of payment terms for Aventon’s B2B buyers. The program is designed to help Aventon’s retail partners buy more confidently and manage working capital more effectively, while supporting the brand’s long-term growth in a new geography. By offering trade credit through TreviPay, Aventon can give retailers greater
Alpaca Expands into Europe with WealthKernel Acquisition and Launch of European Equities Trading21.4.2026 10:49:00 CEST | Press release
Alpaca has completed its acquisition of European fintech WealthKernel, which will now operate as Alpaca Europe The acquisition gives Alpaca a regulated brokerage and custody presence across the UK and EU Alpaca is also launching European equities trading, beginning with Germany’s Xetra exchange, with Euronext markets and the London Stock Exchange expected to follow Alpaca, a global leader in brokerage infrastructure APIs, today announced the completion of its acquisition of European fintech WealthKernel, marking its expansion into Europe. The company also announced the initial rollout of its API-first equities trading services in Europe, enabling cross-border investing through a single integration. WealthKernel will now operate as Alpaca Europe. The acquisition gives Alpaca licensed brokerage and custody infrastructure in the UK and EU, supporting its ability to deliver investment services and expand its wealth management capabilities across the region. Built on WealthKernel’s regulato
Comwrap Reply Recognized With the Adobe CXO Emerging Partner Western Europe Award21.4.2026 09:52:00 CEST | Press release
Comwrap Reply, the Reply company specialised in cloud-native digital experience services, has received the Adobe CXO Emerging Partner Western Europe Award, one of the recognitions presented as part of the Adobe Customer Experience Orchestration Partner Awards, which honour companies that have made significant contributions to Adobe’s business and delivered a tangible impact on customer success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421234434/en/ The award is part of a long-standing collaboration with Adobe, recently reaffirmed by the renewal of Comwrap Reply’s Adobe Platinum Solution Partner status, and highlights the experience gained in developing digital experience solutions on Adobe Experience Cloud. The recognition confirms Comwrap Reply’s role in supporting organisations in the design and evolution of digital platforms based on Adobe Experience Cloud, capable of integrating content, data and customer journe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom